Posted: 19 April 2023 BioMelbourne Network thanks Professor Brendan Murphy AC for his outstanding contributions to health and public health in various roles, including Secretary of the Australian Government Department of Health and Aged Care. “As Chief Medical…
Posted: 19 April 2023 Neuren Pharmaceuticals reported that its North America partner Acadia Pharmaceuticals (NASDAQ: ACAD) has announced that DAYBUE™ (trofinetide) is now available for the treatment of Rett syndrome in adult and pediatric patients two years of…
Posted: 19 April 2023 Starpharma announces that it has completed enrolment and treatment of patients for the Phase 2 clinical trial of its investigational anticancer product DEP cabazitaxel. Encouraging efficacy signals, including significant tumour shrinkage and substantial tumour…
Posted: 19 April 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the initiation of an open-label Phase II trial evaluating eftilagimod…
Posted: 19 April 2023 Amplia Therapeutics Limited is pleased to advise that dosing of the first patient in Cohort 3 of the Company’s ongoing Phase 1b/2a ACCENT clinical trial of FAK inhibitor AMP945 in pancreatic cancer has begun.…
Posted: 19 April 2023 Patrys Limited, a therapeutic antibody development company, is pleased to announce that the US Patent and Trademark Organisation has granted two patents that provide further intellectual property protection for Patrys’ deoxymab antibody technology until…
Posted: 19 April 2023 The Wisconsin Alumni Research Foundation (WARF), which has a mission of supporting research at the University of Wisconsin-Madison, and Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, today announced…
Posted: 19 April 2023 Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, and Syngenta Seeds, one of the world’s leading agricultural technology companies, announced a research partnership focused on screening a targeted genetic…
Posted: 19 April 2023 Respiratory imaging technology disruptor 4DMedical Limited announces that Dr David Shulkin, MD, has assumed an advisory role within the company. As an accomplished and prominent health care system leader, physician, academic, and industry entrepreneur,…
Posted: 17 April 2023 Atmo Biosciences, a company commercialising the world’s first ingestible gas-sensing capsule that provides insights into gut health and microbiome function, is strengthening its US focus with the appointment of experienced medical device executive Chris…
Posted: 12 April 2023 Cynata Therapeutics Limited, a clinical-stage biotechnology company specialising in cell therapeutics, has today announced that it has received approval from the Australian Human Research Ethics Committee (HREC) to commence the proposed Phase 2 clinical…
Posted: 12 April 2023 y Professor David Hunter, Florance and Cope Chair of Rheumatology and Professor of Medicine, University of Sydney and Royal North Shore Hospital Australians living with arthritis pain are parting with thousands of dollars, sometimes tens…